A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL) — TAME-AL

Light Chain (AL) Amyloidosis Clinical Trial

Official title:
A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

Status Completed

Clinical Trial Summary

Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02015312
Study type	Interventional
Source	University Hospital Heidelberg
Contact
Status	Completed
Phase	Phase 2
Start date	April 2013
Completion date	October 11, 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05996406` - Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)	Phase 2
Withdrawn	`NCT05692908` - An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis	Phase 1
Withdrawn	`NCT04943302` - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis	Phase 2
Not yet recruiting	`NCT06097832` - Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis	Phase 1
Recruiting	`NCT05486481` - Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)	Phase 1/Phase 2
Recruiting	`NCT06376214` - Daratumumab for Patients With Light Chain Amyloidosis	N/A
Recruiting	`NCT04973137` - A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis	Phase 3
Recruiting	`NCT04316442` - Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis	Phase 1/Phase 2